Ocata will need to change overtime, and make improvements, that is why Dr Lanza has already patented and is testing second generation RPE cells.
If Ocata is purchased, my guess Lanza will go work somewhere else. The purchasing company then would not have the capabilities to improve its technology. The smartest play is to partner.
There are risks to investing in any phase 1 biotech. The science here is clearly a cut above the entire field. The business side is catching up. The risk right now is that Ocata needs MONEY and a lot of it! Clinical trials are expensive. When there is a clear path in regards to the future financing of this company the market will respond. Right now it's pure manipulation!
Also anyone claiming that the improvements in vision and the patients seeing better for three years due to placebo effect need roll another fat one and smoke it cuz they are out of there mind.
Market Data 
Markets 
AI
